PharmaCyte Biotech

PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes. The company was founded on October 28, 1996 and is headquartered in Las Vegas, NV.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LAGUNA HILLS, Calif.--(BUSINESS WIRE)---- $NASDAQ #AnotherFDARequiedTestPasses--PharmaCyte Biotech participates in the H.C. Wainwright 23rd Annual Global Investment Conference.

PharmaCyte Biotech to Participate in H.C. Wainwright 23rd Annual Global Investment Conference

LAGUNA HILLS, Calif.--(BUSINESS WIRE)---- $NASDAQ #AnotherFDARequiedTestPasses--PharmaCyte Biotech establishes 18-month shelf life for its clinical trial product to be used in its Phase 2b clinical trial, if approved by the FDA.

PharmaCyte Biotech Establishes 18-Month Shelf Life for Clinical Trial Product in Ongoing Stability Study

LAGUNA HILLS, Calif.--(BUSINESS WIRE)---- $NASDAQ #Ascites--PharmaCyte expands product pipeline to include diabetes and malignant ascites following $90 million in capital raises.

PharmaCyte Biotech Expands Product Pipeline to Include Diabetes and Malignant Ascites Following $90-Million Capital Raise

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--PharmaCyte closes $70 million offering and explains how these funds will be used to grow the Company into the future and create shareholder value.

PharmaCyte Biotech Announces Closing of $70 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

I recommend that you nibble a few shares of PharmaCyte Biotech if interested in a “trade” or a very high-risk long-term buy-and-hold. Historically, the company (or its investors) has proved to be quite expert in self-promotion.

PharmaCyte Biotech: Buy The 'Dump'

LAGUNA HILLS, Calif.--(BUSINESS WIRE)---- $NASDAQ #70MillionRaise--PharmaCyte announces $70 million registered direct offering priced At-the-Market under the Nasdaq rules.

PharmaCyte Biotech Announces $70 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

The shares of PharmaCyte Biotech, Inc. (NASDAQ: PMCB) increased by 189.47% yesterday. These are some details you should know.

PharmaCyte Biotech Shares Increased 189.47%: Details

$PMCB was the top trending ticker on Stocktwits as retail traders rallied around the stock's intraday surge.

A small biopharma stock has spiked 187% as retail traders cheer CEO's roadmap for drug development following Nasdaq listing

PharmaCyte Biotech (PMCB) stock is taking off Wednesday and there are a few things that potential investors need to know about the company. The post PMCB Stock: 14 Things to Know About PharmaCyte Biotech as Shares Skyrocket appeared first on InvestorPlace.

PMCB Stock: 14 Things to Know About PharmaCyte Biotech as Shares Skyrocket

The shares of PharmaCyte Biotech, Inc. (NASDAQ: PMCB) increased by over 20% pre-market. This is why it happened.

PharmaCyte Biotech Shares Increase Over 20% Pre-Market: Why It Happened

LAGUNA HILLS, Calif.--(BUSINESS WIRE)---- $NASDAQ #BigBoardStock--PharmaCyte releases statement on Nasdaq uplisting and current business focus.

PharmaCyte Biotech Releases Statement on Nasdaq Uplisting and Current Business Focus

Today, two key catalysts are taking PMCB stock higher, as investors seem to like the positioning of biotech PharmaCyte. The post PMCB Stock: 2 Big Reasons PharmaCyte Biotech Is Soaring 70% Today appeared first on InvestorPlace.

PMCB Stock: 2 Big Reasons PharmaCyte Biotech Is Soaring 70% Today

The shares of PharmaCyte Biotech, Inc. (NASDAQ: PMCB) increased by over 94% during intraday trading. This is why it happened.

PharmaCyte Biotech Shares Increase Over 94% Intraday: Why It Happened

LAGUNA HILLS, Calif.--(BUSINESS WIRE)---- $NASDAQ #BigBoardStock--PharmaCyte Biotech announces closing of its public offering of approximately $15 million.

PharmaCyte Biotech Announces Closing of $15-Million Public Offering

The shares of PharmaCyte Biotech Inc. PMCB, -57.36% plummeted 55.9% in premarket trading Tuesday, ahead of their debut on the Nasdaq exchange on Tuesday, after the biotechnology company announced the terms and pricing of a relatively large public equity offering. The California-based company, which focuses on developing cellular therapies for cancer and diabetes using its live-cell encapsulation technology, expects its stock to start trading on the Nasdaq under the ticker symbol "PMCB" on Tuesday, after previously trading over the counter.

PharmaCyte Biotech's stock loses more than half its value ahead of Nasdaq debut

LAGUNA HILLS, Calif.--(BUSINESS WIRE)---- $NASDAQ #NASDAQ--PharmaCyte Biotech announces uplist date to NASDAQ and pricing of $15 million public offering.

PharmaCyte Biotech Announces Uplist Date to NASDAQ and Pricing of $15 Million Public Offering

LAGUNA HILLS, Calif.--(BUSINESS WIRE)---- $NASDAQ #bigboardstock--PharmaCyte Biotech uplists to Nasdaq and launches a public offering.

PharmaCyte Biotech Announces Uplist to The Nasdaq Capital Market and Launch of Public Offering

LAGUNA HILLS, Calif.--(BUSINESS WIRE)---- $PMCB #DrugDiscovery--PharmaCyte provides update to Nasdaq listing efforts and presents scientific publications supporting pancreatic cancer treatment.

PharmaCyte Biotech Provides Update to Nasdaq Listing Efforts and Presents Scientific Publications Supporting Pancreatic Cancer Treatment

LAGUNA HILLS, Calif.--(BUSINESS WIRE)---- $Nasdaq #Nasdaq--PharmaCyte Biotech updates shareholders on biocompatibility study progress and its plans to uplist to Nasdaq.

PharmaCyte Biotech Announces Update on Study Progress and Uplist to Nasdaq

News for PharmaCyte Biotech Stock (PMCB)